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ABSTRACT : Plasma fibronectin (pFN) in patients with gastric cancer was 
measured by ELISA method in the aspect of clinical significance. And also cellular 
fibronectin (cFN) was detected by means of immunochemical staining to clarify the 
localization of the basal membran and stroma. 
 pFN was a significantly reduced in patients with gastric cancer and hepatocelllular 
carcinoma. In the postoperative course, a peak reduction was observed on day 1 and 
recovery was retarded in patients with gastric cancer. It was ascertained in this study 
that pFN indicated the patient's nutritional states and also reflected the function of the 
reticuloendothelial system. A few carcinomas showed discontinuous staining on the 
surface in some of papillary adenocarcinomas, well differentiated and moderately 
differentiated carcinomas and on the basement membrane of metastatic lymphnodes. 
It is certified that cFN localization correlated well with local invasion and node metastasis, 
and there was nothing to show cFN localization at the sites of deep invasion and involved 
lumen of lymph vessels.
       INTRODUCTION 
 Fibronectin (FN) comprises of a large glyco-
protein and is divided into the two, pFN and 
cFN respectively. pFN is present in plasma and 
body fluide as being soluble protein. It plays 
a key role in blood coagulation, wound heal-
ing and phagocytic activity in the reticu-
loendothelial system as a non-specific opsonin. 
On the other hand, cFN is present in connective 
tissues and basement membranes and it con-
tributes to connection with cells to cells and with 
cells to stromas and to cell extension, cell 
differentiation and cell formation. 
 A few reports are available for malignant 
diseases. In contrast, there is little available 
information on the clinical significance of pFN 
in gastric cancers. There are many devices for 
quantitative determination such as single ra-
dial immunoduffusion, quantitative immuno-
electrophoresis (Laurell' method), immuno-
turbidimetric assay, laser nephelometric assay 
RIA and EIA and so on. 
 The purpose of this study is to clarify changes 
in pFN associated cFN localization at the site 
of basal membrane and stroma in gastric cancer 
in terms of cancer spreading and metastasis into 
the nodes.
    MATERIAL AND METHOD 
 Fifty-one gastric cancer, 24 colon cancer and 
seven hepatoma patients were eligible for this 
study and 20 choleliathis patients with benign 
diseases also were subject to this study. The 
distribution of sex in this study was 54: 48 of 
men to women. The ages ranged from 25 to 
85 years old on the average of 61.3 years old. 
A control of twenty normal individual was
chosen. For pFN measurement, the blood 
samples were taken before surgery on day 1, 
3, 7, 14 respectively and preserved at -80"C, pFN 
was measured by enzym-linked immunosorbent 
assay.2) Anti-rabbit antibody (MBL) was dil-
uated to 1 : 1000 with phosphate buffer saline 
(PBS) in pH7.0 and incubated overnight at room 
temperature in Nunc-immunoplate II, Nunc. 
Inter Med), washed with 0.05% tween-20, adding 
5% BSA and incubated in 0.01M PB at 37°C for 
two hours, washed and incubated at 37°C for 
one hour adding x1000 diluted blood sample to 
standard FN (human, FN concentration 280,ug/ 
ml, Behring inst.), washed and added x400 
peroxidease labelled anti-rabbit, FN antibody 
(MBL), incubated in 100,ul/well at 37CC for one 
hour. After washing, adding 0.4mg/ml, 30% 
H202 4,u1/ml to 100,u/well of citrate buffer pH5.0, 
left to react for 30 min and to cease a reactin 
using 50,u1/well of 4N H2SO4. The pFN values 
were obtained by s pectro photometric measure-
ment in comparison with standrad FN curve. 
Each sample was tested in triplicate and 
compensated for citrate dosis used at sampling. 
The Student's test was used for comparison. 
Materials eligible for immunohistochemical 
study comprised of 76 gastric cancers (five 
papillary adenocarcinomas, 13 well differen-
tiated tubular adenocarcinomas, 17 moderately 
differentiated adenocarcinomas, 27 poorly 
differentiated carcinomas, three medullar carci-
noma, 11 signetring cell carcinomas and 
lymphnodes belonged to each carcinoma). 
 As staining method, ABC method (VECTA 
STAIN ABC KIT, VECTOR LAB) was used for 
this study. Paraffin-embedded preparat was 
dewaxed, indigested at 37°C for two hours and 
washed with PBS (pH7.6) for 15 min, inactivated 
peroxidase with 0.3% H2O2 methanol, washed for 
20 min and inactivated with sheep sera for 20 
min, subsequently incubated with anti-rabbit 
FN antibody (MBL) at room temperature for 60 
min, washed with PBS for 15 min, incubated 
with Biothin-antibody for 60 min at room 
temperature. After washing with PBS, adding 
Avidin Biotin Peroxidase Complex (ABC), 
incubated for 60 min at room temperature and 
reacted with DAB-1102 (diaminobenzidine 20mg/ 
0.05M Tris-HCL, pH7.6 100ml H202 20,ul) for 1-2 
min at room temperature, washing with PBS.
HE was used for nuclear staining.
          RESULT 
a) Clinical evaluation of pFN 
 In normal individual, pFN averaged 398.1 
71.2,ug/ml. Meanwhile, it was 390.1 ±76.6,ug/ml, 
in gastric cancer patients, 385.6±101.6,ug/ml in 
colon cancer patients. There was not signifi-
cantly different between patients without and 
with malignant diseases. On the other hand, 
it was lower in patients with hepatoma than in 
healthy persons with significant difference (p< 
0.01). In patients with cholelithiasis, pFN was 
somewhat increased without significant differ-
ence. 
 According to the general rule of gastric cancer 
study4), pFN values in accordance with the 
disease stage were shown in Fig. 1, stage I was 
42.1±84.5,ug/ml, stage II 393.6±38.5,ug/ml, stage 
III 379±65.4,ug/ml, stage IV 342.3±59.1,ug/ml. 
In advances in disease stages, pFN values were 
reduced and there was significantly different
Fig. 1. Preoperative pFN levels in patients with 
      gastric cancer according to staging of the 
      General Rules of the Gastric Cancer Study
Table. 1. Preoperative pFN levels in patieets and normal controls 
       Group Number Mean±S. D. Levels of                                (
,ug/ml) significance 
 Malignant disease 
    Gastric cancer 51 390.0± 76.6 NS 
    Colorectal cancer 24 385.6±101.6 NS 
    Hepatoma 7 275.1± 51.5 P<0.01 
Benighn disease 
   Cholelithiasis 20 426.6± 78.3 NS 
 Normal controls 20 398.1± 71.2
Fig. 2. Preoperative pFN levels in patients with 
       colorectal cancer according to Dukes'
      classification
(p<0.01) between stage I and stage IV. 
 On the other hand, pFN in patients with colon 
cancer showed 421.6±114.3,ug/ml in Dukes A, 
425.0±102.3,ug/ml in Dukes B, 341.2±69.8,ug/ml 
in Dukes C in accordance with Dukes' classifica-
tion. There was a significant difference (p<0.05) 
between Dukes A and C as shown in Fig. 2. 
pFN values were reduced in cases of Borrmann 
IV type, serosal invasion (ssr-sei) in the depth 
of cancer infiltration and signet ring cell 
carcinoma of histologic types without statistially 
significant difference as shown in Fig. 3. 
 Fig. 4 showed changes in pFN values in the
Fig. 3. Preoperative pFN levels in patients with 
       gastric cancer according to Borrmann's
      type, depth of invasion and histopathology 
      of the General Rules for the Gastric Cancer 
     Study
postoperative course according to the disease 
stage of gastric cancer. These were significantly 
reduced on day 1, followed by recovery to the 
prior level after on day 3. Delay in recovery 
from redued pFN was observed in stage IV 
patients with gastric cancer. The correlation 
with pFN values and the other clinical data were 
evaluated between the two groups of more than 
400,ug/ml of pFN and less. As shown in Table 
2, a significant disparity (p<0.01-0.05) was
Table 2. Comparison of pFN levels and other hematologic parameters 
                   PFN401 < PFN400> 
                        (n=32) (n=56) t-test 
 Plasma Fibronectin 489.3±56.3 329.4±53.1 -
 WAC 6220±1900 5850±2230 n. s. 
 Lymph. C. 2140±740 1650±480 1% 
 Monocyte 483±233 386±164 5% 
 Platelet (X 104) 24.9±8.1 22.9±9.9 n. s. 
 Total Protein 6.7±0.4 6.6±0.6 n. s. 
 Albumin 3.9±0.3 3.7±0.4 5% 
 GOT 35.5±60.8 22.7±23.1 n. s. 
 GPT 52.1±126.2 22.1±26.3 n. s. 
 Fibrinogen 304±82 301±10.0 n. s.
Fig. 4. Postoperative changes of pFN levels in 
      patients with gastric cancer according to
      staging of the General Rules for the Gastric
      Cancer Study
noted between pFN values and lymphocyte and 
monocyte counts, and albumin levels. 
b) Immunohistochemical study on cFN 
 The epithelium in normal gastric tissues was 
not immunohistologically stained. However, 
continuous staining of cFN was observed in the 
basement membrane of epithelial cells which 
formed glandular duct (Fig. 5). 
 Striated FN staining was observed in the 
basement membrane of glandular ducts in the 
field of dysplastic epithelium. (Fig. 6). 
 According to histologic types, discontinuous 
and irregular cFN staining was noted at the site 
of the basement membrane in spite of no 
staining on the surface of the epithelium in
cancer cells and cytoplasmas (Fig. 7). In 
identical patient, there was nothing to be stained 
in deeply invasive lesions and glandular 
organization (Fig. 8). The surface of the 
epithelium in well differentiated carcinoma was 
discontinuously and irregularly stained but it 
was very faint. In contrast, cFN was diffusely 
stained in stromas surrounded by glandular 
structure (Fig. 9). A strong line bordering cFN 
staining stromas around glandular structure 
was present in the deepli invasive lesions in 
spite of no staining of glandular basement 
membrane as well as the sites involved by 
carcinoma, cFN was densely stained in stromas 
surrounded by the tumor but there was not 
stained in cancer cells as well as basement 
membrane (Fig. 11). With respect to metastatic 
nodes, irregular and weak cFN staining was 
seen in the glandular basement membrane and 
it was identical to cFN localization on the 
surface of tumor cells (Fig. 12). Even in poorly 
differentiated carcinoma, the modes of cFN 
staining of metastatic nodes were the same as 
those on the surface of tumor cells. 
 cFN localizations by ABC method were 
summarized in Table 3. Neither the surface of 
tumor cells nor cytoplasma posed cFN 
localization regardless of histologic types. 
There were many cases with an expression of 
cFN of glandular basement membrane on the 
surface of the tumor cells in patients with 
papillary adenocarcinoma, well and mode-
rately differentiated, tubular adenocarcinoma.
Fig. 5. cFN staining in normal mucosa (ABC 
     method x 400)
Fig. 8. cFN staining in deeply invasive site of 
      papillary adenocarcinoma (ABC method x 
     200)
Fig. 6. cFN staining in atypical epithelium (ABC 
      method x 200)
Fig. 9. cFN staining on the surface of well 
      differentiated tubular adenocarcinoma
     (ABC method X100)
Fig. 7. cFN staining on the surface of papillary 
      adenocartinoma (ABC method X200)
Fig. 10. cFN staining in deeply invasive site of well 
      differentiated tubular carcinoma
Fig. 11. cFN staining in poorly differentiated adeno-
      carcinoma (ABC method x 100) Fig. 12. cFN staining in metastatic lymphnode from 
      papillary adenocarcinoma (ABC method x 
     200)
Table. 3. Fibronection localization in gastric cancer , ABC staining with anti FN 
        antiserum
Histo- C
ancer Basement membrane pathological N
umber 
cell Superficial Deep invasive Stroma type 
part part 
  pap 5 (-) (+) 4/5 (80%) (-) (+) 
  tubl 13 (-) (+)10/13 (77%) (-) (+) 
  tub2 17 (-) (+) 9/17 (53%) (-) (+) 
   por 27 (-) (-) (-) (+) 
   sig 11 (-) (-) (-) (+) 
   muc 3 (-) (-) (-) (+)
Table.4. Basement membrane cFN of primary tumors and reginal 
        metastatic lymphnodes in gastric cancer
                  Positive NO. (%) of Basement 
Lymphnode membrane cFN 
metastases Reginal metastatic               Pri
mary tumor l
ymphnodes 
 nl (+) 5/6(83%) 4/6(67%) 
 n2 (+) 4/6 (67%) 3/6(50%) 
 n3 (+) 3/5(60%) 2/5(40%)
 Positive rates of cFN staining were higher in 
papillary adenocarcinoma and lower in moder-
ately differentiated carcinoma. On the other 
hand, even though cFN staining on the surface 
of tumor cells were positive, cFN localization 
was not seen in glandular basement membrane 
where cancer infiltration was deeply extending. 
Furthermore, cFN staining was negative in 
glandular basement membrane on the surface 
of tumor cells and deeply invasive site in poorly 
differentiated, signet ring cell and medullary
carcinomas. Nevertheless, the intensity of cFN 
staining was attributable to connective tissue 
volume although it was positive in all histologic 
types. 
 Next, cFN positive rates in glandular base-
ment membrane of metastatic nodes were 
compared between primary tumor foci and 
metastatic nodes (Table 4). 
 With advancing in node metastasis, the 
positive membrane were reduced in evaluation 
of the patients with ni (+) in six, n2 (+) in six
and n3 (+) in five. In addition, cFN staining 
positive rates in neighbouring node with metas-
tasis also revealed a reduction with progression 
of metastasis.
         DISCUSSION 
 FN has been introduced as a plasma protein 
in 19845) and it called cold insoluble globulin. 
Thereafter similar protein was detected on the 
surface of fibroblasts6) and it was named large 
external transformation sensitive (LETS) pro-
tein 1 because of disappearance on the surface 
of the membrane with advances in malignancy. 
Later it was recognized that both were the same. 
Mosher') called it fibronectin. It is assumed that 
pFN contributes to blood cooagulation, wound 
healing, excretion of foreign body and de-
bridement with the fanction of the reticu-
loendothelial system'). It is accepted that pFN 
reduced in case of burn, sepsis, DIC, surgical 
insult8-101. Kikuchi" reported that pFN levels 
reduced in acute fulminating phase of crohn' 
disease and ulcerative colitis. In contrast, those 
increased in remitting phase. On the other hand, 
pFN levels in malignant diseases were 
investigated. Choate12> clarified that pFN levels 
incrased in colon cancer and breast cancer 
irrespective of metastasis. The same reports 
were published by Blumenstock13) in lung 
cancer, by Stathakis14) in pancreas cancer with 
obstructive jaundice. Nevertheless, Nishimura15) 
reported not significant difference in pFN levels 
between patients with benign and malignant 
diseases. 
 In this series, pFN levels revealed not signifi-
cant difference between healthy and diseased 
subjects in spite of a decrease in hepatoma. 
There was disagreement among various authors 
concerning pFN levels in benign and malignant 
diseases. Choate12) investigated that disparity 
of pFN levels did not correspond to progre-
ssion of diseases but was contributary for 
patient's condition. The validity of a tumor 
marker of pFN levels might be impared on the 
basis of a result that pFN levels were in 
associated with patient's condition and nutri-
tion. Takeuchi16) insisted that FN levels in urine 
increased with progression of the tumors and 
measurement of urin FN were of great benefit
to know the progression of malignant diseases. 
 In this study, it was confirmed that pFN levels 
were influenced by nutritional condition in 
patients and function of the reticuloendothelial 
system. As for changes in pFN levels in the 
postoperative course, Matsuda") reported that 
pFN levels varied in accordance with surgical 
stress, a transient decrease in pFN levels was 
observed in early postoperative period due to 
enhanced availability and consumption around 
the wound. Gauperaa18) clarified that pFN levels 
reached to a peak reduction immediately after 
surgery, followed by gradual increase, still 
maintaining lower levels even in 120 hours later 
by using immunoturbidimetric assay in analysis 
of 72 patients. He explained that a decrease in 
pFN levels was based on FN sequestration. 
Nishimura15) also reported that there was a 
significant decrease in pFN levels on day 1 and 
3 and complete recovery on day 7. The resuts 
in this series were consistent with their 
conclusions. 
 The use of ELISA technique was first 
attempted to measure FN in 1971 by Engvall18. 
Recent studies suggest the advantage of this 
technique is in a specific reaction with a small 
amount of antigen and antibody without the use 
of radioactive isotope with high sensitivity 
equivalent to that in RIA method"). pFN level 
by using ELISA method in normal individual 
of this study remained still higher as compared 
to those reported by other investigators", 12) 
ZerlauthL8> clarified that the reasons for high 
levels obtained by ELISA and EIA methods are 
that FN is excessively sensitive to response to 
proteolysis and much more responds to small 
fragments rather than antigenecity, due in part 
to the use of pFN polyclonal antibody, not 
monoclonal antibody. 
 Many investigators have been studied on the 
relationship between cFN levels and neoplastic 
and/or metastatic diseases. Vaheri21' reported 
a possible fact that FN disappered from the 
surface of cells transfromed to malignancy. 
Smith 221 also reported that FN production of 
culture cells from parent cells of human cancer 
cells was compared among culture cells. As a 
result, he clarified that FN production of 
cultured metastatic cells was inferior to that of 
non-metastatic cells. In comparative study in
FN distribution between metastatic and 
non-metastatic breast cancer cells, Labat-
Robert23> reported positive FN staining sites in 
non-metastatic cells distributed in the line 
bordering cells and basement membrane in 
contrast with negative staing in metastatic cells. 
In fact, many reports evidenced negative cFN 
staining was characteristic of metastatic cells 
with high potential. 
 Stenman24> showed FN staining in solid 
tumors by using immunofluorence method and 
they compared the modes of FN staining 
between carcinomas and sarcomas. It was 
clarified that in sarcomas FN staining showed 
a network of FN staining in connection with 
stromas, meanwhile in carcinomas staining in 
cancer cells and/or around cells was not. In 
their conclusions, the findings of FN staining 
are of great benefit to differentiate between the 
two. 
 On the other hand, Christensen25> reported 
stronger cFN staining in cytoplasma of ma-
lignant cells according to poorly differentiated 
intensity and he clarified a difference in cFN 
localization in accordance with histologic types. 
Nagai26> reported that FN localization was seen 
around cells in poorly differentiated and 
undifferentiated lung cancers. On the contrary, 
it was only in stroma in well differentiated lung 
cancers. In contrast, Tagiridar27> showed FN 
localization inside and outside hepatoma cells 
by using biotin fluoresceinated-avidin method. 
It is concluded from the above reports that 
diversity of FN localization is in association with 
primary organs and histologic types. 
 Burtin28> cited that FN antigen diffusely 
located in peritumorous stroma, in contrast in 
the basement membrane it is difficult to express 
FN antigen because of dense staining in 
peritumorous connective tissues. Forster29> 
studied on distribution of FN and laminin by 
means of PAP method in 50 patients with rectal 
cancer. He concluded that FN distributed in 
the basement menbrane of glandular carcinoma 
cells although FN and laminin distributions 
were noted in stromas. On the other hand, 
Maeda38> reported that FN antigens in gastric 
cancer cells were present in the basement 
membrane and stroma regardless of cell 
differentiation by using immunofluorescence
method. On the basis of a result that cFN failed 
to stain in gastric cancer cells irrespective of 
histologic types in this series, it is suggestive 
that the deeper cancer infiltration, the more 
would cFN staining become reduced. 
 As reported by many investigators,28 3o> there 
was close correlation with the amount of 
connective tissues and the intensity of cFN 
staining. It is reasoned that either host response 
or cFN production might be facilitated in 
accordance with progression of the tumor. In 
this study, it is emphasized that node metastasis 
correlates well with cFN staining in the 
basement membrane. 
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